Discovery of GDC-0994, a potent and selective ERK1/2 inhibitor in early clinical development

被引：10
|
作者：
Robarge, Kirk [1 ,2 ]
Schwarz, Jacob [1 ,2 ]
Blake, Jim [1 ,2 ]
Burkard, Michael [1 ,2 ]
Chan, Jocelyn [1 ,2 ]
Chen, Huifen [1 ,2 ]
Chou, Kang-Jye [1 ,2 ]
Diaz, Dolores [1 ,2 ]
Gaudino, John [1 ,2 ]
Gould, Stephen [1 ,2 ]
Grina, Jonas [1 ,2 ]
Xin Linghu [1 ,2 ]
Liu, Lichuan [1 ,2 ]
Martinson, Matthew [1 ,2 ]
Moreno, David A. [1 ,2 ]
Orr, Christine [1 ,2 ]
Pacheco, Patricia [1 ,2 ]
Qin, Ann [1 ,2 ]
Rasor, Kevin [1 ,2 ]
Ren, Li [1 ,2 ]
Shahidi-Latham, Sheerin [1 ,2 ]
Stults, Jeffrey [1 ,2 ]
Sullivan, Francis [1 ,2 ]
Wang, Weiru [1 ,2 ]
Yin, Peter [1 ,2 ]
Zhou, Aihe [1 ,2 ]
Belvin, Marcia [1 ,2 ]
Merchant, Mark [1 ,2 ]
Moffat, John G. [1 ,2 ]
机构：
[1] Genentech Inc, San Francisco, CA USA
[2] Array Biopharma, Boulder, CO USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-DDT02-03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
DDT02-03
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Discovery of GDC-0994, a potent and selective ERK1/2 inhibitor in early clinical development
    Schwarz, Jacob
    Blake, James
    Burkard, Michael
    Chan, Jocelyn
    Chen, Huifen
    Chou, Kang-Jye
    Diaz, Dolores
    Dudley, Danette
    Gaudino, John
    Gould, Stephen
    Grina, Jonas
    Hunsaker, Thomas
    Liu, Lichuan
    Martinson, Matthew
    Moreno, David
    Orr, Christine
    Pacheco, Patricia
    Qin, Ann
    Rasor, Kevin
    Ren, Li
    Robarge, Kirk
    Shahidi-Latham, Sheerin
    Stults, Jeffrey
    Sullivan, Francis
    Wang, Weiru
    Yin, Jianping
    Zhou, Aihe
    Belvin, Marcia
    Merchant, Mark
    Moffat, John
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 252
  • [2] Development of a Practical Synthesis of ERK Inhibitor GDC-0994
    Xin Linghu
    Wong, Nicholas
    Iding, Hans
    Jost, Vera
    Zhang, Haiming
    Koenig, Stefan G.
    Sowell, C. Gregory
    Gosselin, Francis
    [J]. ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2017, 21 (03) : 387 - 398
  • [3] Development of a practical synthesis of ERK inhibitor GDC-0994
    Wong, Nicholas
    Xin Linghu
    Gosselin, Francis
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 253
  • [4] Development of a practical synthesis of ERK inhibitor GDC-0994
    Wong, Nicholas
    Linghu, Xin
    Koenig, Stefan
    Zhang, Haiming
    Jost, Vera
    Fantasia, Serena
    Gosselin, Francis
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 252
  • [5] A Phase Ib Study to Evaluate the MEK Inhibitor Cobimetinib in Combination with the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors
    Weekes, Colin
    Lockhart, Albert
    LoRusso, Patricia
    Murray, Elaine
    Park, Erica
    Tagen, Mike
    Singh, Jatinder
    Sarkar, Indrani
    Mueller, Lars
    Dokainish, Hatem
    Shapiro, Geoffrey
    Burris, Howard
    [J]. ONCOLOGIST, 2020, 25 (10): : 833 - +
  • [6] Practical synthesis of ERK inhibitor GDC-0994 on multi-kilogram scale
    Xin Linghu
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 252
  • [7] A Phase Ib study to evaluate the MEK inhibitor cobimetinib in combination with the ERK1/2 inhibitor GDC-0994 in patients with advanced solid tumors
    Weekes, Colin D.
    Lockhard, Albert
    LoRusso, Patricia
    Murray, Elaine
    Park, Erica
    Tagen, Michael
    Mueller, Lars
    Dokainish, Hatem
    Shapiro, Geoffrey
    Burris, Howard
    [J]. CANCER RESEARCH, 2017, 77
  • [8] A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors
    Varga, Andrea
    Soria, Jean-Charles
    Hollebecque, Antoine
    LoRusso, Patricia
    Bendell, Johanna
    Huang, Shih-Min A.
    Wagle, Marie-Claire
    Okrah, Kwame
    Liu, Lichuan
    Murray, Elaine
    Sanabria-Bohorquez, Sandra M.
    Tagen, Michael
    Dokainish, Hatem
    Mueller, Lars
    Burris, Howard
    [J]. CLINICAL CANCER RESEARCH, 2020, 26 (06) : 1229 - 1236
  • [9] A first-in-human phase I study to evaluate the ERK1/2 inhibitor GDC-0994 in patients with advanced solid tumors
    Varga, A.
    Soria, J. C.
    Hollebecque, A.
    LoRusso, P.
    Vaishampayan, U.
    Okrah, K.
    Huang, S. M. A.
    Murray, E.
    Sanabria-Bohorquez, S.
    Tagen, M.
    Dokainish, H.
    Mueller, L.
    Burris, H.
    [J]. EUROPEAN JOURNAL OF CANCER, 2016, 69 : S11 - S11
  • [10] The ERK inhibitor GDC-0994 selectively inhibits growth of BRAF mutant cancer cells
    Chen, Yulu
    Sang, Ye
    Li, Shiyong
    Xue, Junyu
    Chen, Mengke
    Hong, Shubin
    Lv, Weiming
    Sehgal, Kartik
    Xiao, Haipeng
    Liu, Rengyun
    [J]. TRANSLATIONAL ONCOLOGY, 2024, 45
12345